Table 1.

The objective response rates of “immune active” tumors and “immune quiescent” tumors to immune checkpoint inhibitors.

Classification	Tumor type	Objective Response Rates	References
Immune active tumors	Melanomas (with a combinational treatment of nivolumab and ipilimumab)	53%	Wolchok et al., 2013
	Non-small cell lung cancer (Squamous cell type)	20%	Brahmer et al., 2015
	Non-small cell lung cancer (Adenocarcinoma)	19.2%	Paz-Ares et al., 2015
	Gastroesophageal adenocarcinoma (PD-L1+ tumor)	22%	Muro et al., 2015
	Colorectal carcinoma (MSI tumors)	40%	Le et al., 2015a
	Renal cell cancer	20–30%	Motzer et al., 2015; McDermott et al., 2015
	Squamous cell carcinoma of the head and neck	18.2%	Seiwert et al., 2015
	Hepatocellular carcinoma	23%	El-Khoueiry et al., 2015
	Hodgkin’s Lymphoma	87%	Ansell et al., 2015
Immune quiescent tumors	Pancreatic adenocarcinoma	~0%	Brahmer et al., 2012
	Colorectal carcinoma (MSS tumors)	0%	Le et al., 2015a
	Non-responsive melanoma, NSCLC, GA, RCC, SCCHN, HCC, etc.	0%	See above

NSCLC, non-small cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; HCC, hepatocellular carcinoma; GA, gastroesophageal adenocarcinoma; RCC, renal cell carcinoma; MSI, microsatellite instable; MSS, microsatellite stable.